Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Sodium hydride → 2-Methyl-5-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-quinoxaline
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | Sodium hydride | HCID 24758 | — |
| 반응물 | 4-Chloro-6-(4-(trifluoromethyl)phenyl)pyrimidine | HCID 16747837 | — |
| 반응물 | 2-Methylquinoxalin-5-ol | HCID 135546994 | — |
| 용매 | Dimethylformamide | HCID 6228 | — |
| 생성물 | 2-Methyl-5-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-quinoxaline | HCID 21865291 | — |
반응 단계
The title compound was prepared analogous to the procedure in Example 29 using 4-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine, (Example 2(a), Method A), (0.20 g, 0.77 mmol), 2-methyl-quinoxalin-5-ol (0.14 g, 0.85 mmol, J. Med. Chem, 1988, 41, 4062.) DMF (3 mL), and a 60% dispersion of sodium hydride in mineral oil (0.040 g, 1.0 mmol, Aldrich). Purification by flash chromatography (0→75% EtOAc/hexanes) gave the title compound as an ivory powder. Mp: 135–141° C., MS (ESI, pos. ion) m/z: 383 (M+1).
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US07148221B2 |
| 출처 데이터셋 | uspto-grants-2006_12 |
| ORD ID | ord-6e35f11dcd4244a5a3c13723b33a9a7e |
| 출처 메모 | uspto-grants-2006_12 |